Codagenix utilizes our breakthrough platform technology termed SAVE (Synthetic Attenuated Virus Engineering) to construct live-attenuated viral vaccines against multiple targets. All live-attenuated vaccines that are currently used in the clinic were developed using a trial-and-error based method developed in the 1880s, pre-dating the discovery of the DNA double helix. Codagenix presents a breakthrough approach to live-attenuated vaccine design. The SAVE platform instead relies on synthetic biology and the rational "re-design" of a target virus' entire genome to yield a vaccine strain. This customization process uses software-based algorithms to 're-code' the genome of a target virus. SAVE-'re-coding' results in a vaccine virus with proteins 100% identical to the target strain, ensuring the best possible antigenic match, but possesses a genome that renders it attenuated in the host. SAVE is an up-stream approach to vaccine construction. The science behind the SAVE 're-design' targets a fundamental process of all viruses and thus it is viewed as platform that will yield a pipeline of candidate vaccine strains against multiple targets that include: Influenza virus, Dengue Virus, Respiratory Syncytial virus, poliovirus, and others.